For research use only. Not for therapeutic Use.
Bempedoic acid-d4 (CAS: 2408131-70-2), a premium pharmaceutical research compound designed for advanced lipid-lowering and cardiovascular studies. As a deuterated analog of Bempedoic acid, it offers enhanced stability and improved pharmacokinetic properties. Bempedoic acid-d4 is ideal for use in pharmacological and biochemical research, providing precise and reliable data for your studies. This high-purity compound ensures consistent results, aiding in the development of novel therapies for hyperlipidemia and cardiovascular diseases. Trusted by leading laboratories, Bempedoic acid-d4 is your go-to solution for cutting-edge cardiovascular research. Unlock new possibilities in cholesterol management and heart disease treatment with Bempedoic acid-d4, where innovation meets reliability.
| Catalog Number | S000199 |
| CAS Number | 2408131-70-2 |
| Molecular Formula | C19H32D4O5 |
| Purity | ≥95% |
| Target | PI3K/Akt/mTOR |
| IUPAC Name | 7,7,9,9-tetradeuterio-8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid |
| InChI | InChI=1S/C19H36O5/c1-18(2,16(21)22)13-9-5-7-11-15(20)12-8-6-10-14-19(3,4)17(23)24/h15,20H,5-14H2,1-4H3,(H,21,22)(H,23,24)/i11D2,12D2 |
| InChIKey | HYHMLYSLQUKXKP-AREBVXNXSA-N |
| SMILES | [2H]C([2H])(CCCCC(C)(C)C(=O)O)C(C([2H])([2H])CCCCC(C)(C)C(=O)O)O |
| Reference | [1]. Pinkosky SL, et al. AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism. J Lipid Res. 2013 Jan;54(1):134-51. [2]. Filippov S, et al. ETC-1002 regulates immune response, leukocyte homing, and adipose tissue inflammation via LKB1-dependent activation of macrophage AMPK. J Lipid Res. 2013 Aug;54(8):2095-108. [3]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |
